SecBot SecBot
PRESS-RELEASE ·Filed May 7, 2026

SLDB

Solid Biosciences Inc.
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The Phase 3 initiation and positive EMA PIP opinion de-risk SGT-003's regulatory pathway. Monitor for interim data readouts from INSPIRE DUCHENNE and further FDA interactions, which could drive significant upside.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$7.07
T+0 close · May 7, 2026 · via day close
Latest settled
+13.44%
T+60 · $8.02
Vs SPY
+9.60%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $7.07entry
  2. T+1 · 6mo ago +2.83%α +2.00% · $7.27
  3. T+5 · 6mo ago +4.38%α +2.88% · $7.38
  4. T+20 · 6mo ago −3.11%α −6.25% · $6.85
  5. T+60 · 4mo ago +13.44%α +9.60% · $8.02
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Solid Biosciences dosed the first participant in its Phase 3 IMPACT DUCHENNE trial for SGT-003, a gene therapy for Duchenne muscular dystrophy, and received a positive EMA opinion on its Pediatric Investigation Plan. The company has dosed 46 participants in the Phase 1/2 INSPIRE DUCHENNE trial with generally well-tolerated safety data as of May 4, 2026. This milestone advances SGT-003 toward potential accelerated approval and global regulatory authorizations.

Key Facts

  • First participant dosed in Phase 3 IMPACT DUCHENNE trial (placebo-controlled, randomized, double-blind) for SGT-003 in Duchenne muscular dystrophy.
  • Received positive EMA opinion on Pediatric Investigation Plan (PIP) for SGT-003, establishing pediatric development framework in Europe.
  • 46 participants dosed with SGT-003 in Phase 1/2 INSPIRE DUCHENNE trial as of May 4, 2026 safety cutoff; generally well tolerated with no drug-induced liver injury, myocarditis, thrombotic microangiopathy, or atypical hemolytic uremic syndrome.
  • FDA alignment reached on Phase 3 trial design including primary endpoint of change in time to rise from supine (TTR) velocity at 18 months.
  • SGT-003 has FDA Fast Track, Rare Pediatric, and Orphan Drug designations; also received UK Innovation Passport under ILAP.
  • Duchenne affects ~1 in 5,000 live male births with estimated 10,000-15,000 cases in the US.

Financial Impact

No financial figures disclosed; clinical milestone with potential for future revenue if approved.

Risk Factors

  • Clinical trial failure or safety issues in Phase 3 could halt development.
  • Regulatory delays or negative FDA/EMA decisions on approval pathways.
  • Competition from other Duchenne gene therapies (e.g., Sarepta's Elevidys).
  • Need for substantial additional capital to fund ongoing trials and commercialization.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3289921

Track record

14 reports on SLDB

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +20.77% at T+20 after the Mar 19, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $6.84 Now $6.48 −5.26% settles Dec 15
  2. Nov 6, 202610d ago SC 13D/A Neutral 3/10 Entry $7.02 Now $6.48 −7.69% settles Dec 8
  3. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $6.18 Now $6.48 +4.85% settles Dec 4
  4. Aug 6, 202614w ago S-3ASR Neutral 4/10 Entry $8.39 to $10.25 Now $6.48 −22.77% ▲ +22.17% +22.57% vs SPY
  5. May 12, 202626w ago Press Release Bearish 6/10 Entry $7.38 to $7.22 Now $6.48 +12.20% ▲ +2.17% +1.56% vs SPY
  6. May 7, 202627w ago Press Release Bullish 7/10 Viewing Entry $7.07 to $6.85 Now $6.48 −8.35% ▼ −3.11% −6.25% vs SPY
  7. Apr 23, 202629w ago DEFA14A Neutral 3/10 Entry $7.92 to $6.50 Now $6.48 −18.18% ▼ −17.93% −21.96% vs SPY
  8. Apr 10, 202631w ago 8-K Neutral 2/10 Entry $8.39 to $7.68 Now $6.48 −22.77% ▼ −8.46% −16.19% vs SPY
  9. Apr 1, 202632w ago EFFECT Bearish 7/10 Entry $7.38 to $7.05 Now $6.48 +12.20% ▲ +4.47% +14.19% vs SPY
  10. Mar 19, 202634w ago Press Release Bullish 8/10 Entry $7.03 to $8.49 Now $6.48 −7.82% ▲ +20.77% +11.45% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026